[The results of a clinico-immunological examination of patients with infectious-allergic bronchial asthma undergoing treatment with the polybacterial immunostimulant Respivax].

Twenty patients with infectious allergic bronchial asthma were treated for 4 months with the polybacterial immunostimulator Respivax combined with the maintenance therapy using corticosteroids and bronchospasmolytics. The results show a considerable improvement of the clinical parameters on days 45, 120 and 240 of the treatment. The spirometric indicators improved in more than 50% of the patients. Study of the immune parameters in the serum and saliva indicates an appreciable lowering of the activity of the inflammatory response in the bronchial mucosa, improvement of the specific and nonspecific immune parameters and noticeable positive dynamics of cellular immunity.